Market news

Detailed price information for Sanofi-Aventis S.A. ADR (SNY-Q) from The Globe and Mail including charting and trades.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

French pharmaceutical maker’s site is also designed to provide new capacity for vaccine production in event of another pandemic

Sanofi today inaugurated the Charles Best Building, a flu vaccine manufacturing facility that will manufacture Sanofi's Fluzone® High-Dose influenza vaccine. This new manufacturing facility also offers industrial scale capacity to strengthen Canada's preparedness for future pandemics. The $925 million (CAD) investment includes $415 million in partnership from the Government of Canada and $55 million from the Government of Ontario, marking the single-largest investment in a biomanufacturing facil

Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue base. Click here to read an analysis of SNY stock now.

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R. Duane Clark II and James Sapirstein, R.Ph., MBA, to its Board of Directors. The appointments add commercial and strategic ope

Sanofi and Cheplapharm to create new strategic partnership in mature medicines Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014. The partn

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,415,546,786Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early

The European Commission has cleared €400 million in German state aid for Sanofi to build a new insulin factory in Frankfurt, securing Europe's only human insulin production site. The European Commission, which scrutinizes state aid such as this to prevent distortions of competition, announced on Tuesday that the company could be compensated for its net costs.

Sanofi is partnering with Emmy Award-winning actress, entrepreneur and mom Keke Palmer to help educate families about the importance of protection against serious RSV lung infection for babies. After she discussed the risks of RSV with her son's doctor, Palmer's baby received BEYFORTUS® (nirsevimab-alip), a monoclonal antibody approved to help prevent serious RSV lung infection in newborns and infants entering their first RSV season, as well as in children up to 24 months of age who remain at ri

Opportunities center on inherited disorders, oral drugs, homecare and emerging markets, alongside cell-therapy partnerships, generics, targeted drugs and T-cell innovation Aplastic Anemia Market Aplastic Anemia Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Aplastic Anemia Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The global aplastic anemia market reached approximately $6.92 billion in 2025, expanding at a compound annual gro

Its experimental multiple sclerosis treatment succeeded in a pair of studies.

Sanofi (ENXTPA:SAN) has permanently halted its Phase 3 RSV vaccine trial in infants and toddlers following a serious adverse event involving an infant death. The death was later linked to an underlying health condition that should have excluded the child from the study, prompting questions about trial screening procedures. The decision has drawn heightened regulatory attention, including Freedom of Information Act requests to the FDA, and raises concerns about RSV vaccine safety in very...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The FDA approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Aug. 27.

Questions remain over formal federal recommendations for which Americans should get a vaccine, which could complicate availability of the shots in a handful of states. The spread of the virus remains low.

Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease.

The company has increased its dividend for 30 consecutive years.

Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach Atrial Fibrillation Market Atrial Fibrillation Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Market by Treatment, Type of Drug, Type of Drug Molecule, Type of Target, Route of Administration, Type of Device, Type of Technology, End User, Geographical Regions and Sales Forecast - Trends and Forecast Till 2035" has been added to

Sanofi stock is coming off a mixed three year stretch, with the share price down about 10.5%, yet current valuation checks on earnings and cash flow multiples still suggest the shares lean toward the undervalued side rather than clearly expensive. Over the past three years Sanofi has delivered a share price decline of around 10.5%, which raises the question of whether the current price is better explained by softer expectations or by an opportunity in a stock that has lagged. Partnership...

Sanofi stock reaction to TD Cowen conference spotlight on immunology and rare diseases Sanofi (ENXTPA:SAN) is set to present at the TD Cowen Hot Wheels Tour in New York on 12 August 2026, with senior leaders highlighting its immunology, inflammation, and rare disease franchises. For investors watching Sanofi stock, the focus will be on how management frames the role of immunology and rare blood disorder development within its broader biopharma business, and what this might signal about...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,415,546,786Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company’s decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline review under CEO Belén Garijo, who chose to pull the plug […]

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi was previously approved in

Sanofi (ENXTPA:SAN) drew fresh investor attention after reporting €1,031 million of intangible asset impairments for Q2 2026, along with completing a €1,009 million share buyback covering 1.05% of its share count. See our latest analysis for Sanofi. At a share price of €74.47, Sanofi’s recent 1 day share price return of 2.34% contrasts with a weaker year to date share price return, while the 5 year total shareholder return of 6.98% points to relatively modest long term progress. If Sanofi’s...